Sep 2026· Cancer Reports· Vol 9· 0 citations· 37 references
Medicine
TL;DR
This study aims to systematically decipher the metabolic‐immune interplay in ccRCC through multi‐omics integration, with the goal of identifying robust prognostic biomarkers and actionable therapeutic vulnerabilities.
Abstract
Clear cell renal cell carcinoma (ccRCC) is hallmarked by profound metabolic reprogramming; however, its intricate crosstalk with the tumor immune microenvironment (TIME) and its clinical ramifications remain inadequately elucidated. This study aims to systematically decipher the metabolic‐immune interplay in ccRCC through multi‐omics integration, with the goal of identifying robust prognostic biomarkers and actionable therapeutic vulnerabilities.
Single-cell, spatial transcriptomic and multi-omics analyses reveal endothelial-enriched RAPGEF2 in KIRC and Experimental validation links RAPGEF2 to tumor suppression and immunotherapy benefit.
Yan-Fei Chen, Xiao-Xue Yu, Chao Cai et al.· Translational Oncology· 0 citations
Highlights • FABP4 is broadly downregulated across five gynecologic malignancies.• Promoter hypermethylation is associated with reduced FABP4 expression.• High FABP4 marks poor ovarian/cervical but favorable endometrial outcomes.• Single-cell and spatial data link stromal FABP4 to metabolic–immune crosstalk.• FABP4 kno...
Highlights ● Multi-omics analysis identifies a robust three-gene prognostic signature for LUAD.● The signature stratifies patients by survival and tumor immune characteristics.● High-risk tumors display proliferative programs and immunotherapy-related features.● The model predicts differential responsiveness to immune...
Huangkai Zhu, Yannan Fang, Minglei Yang et al.· Translational Oncology· 0 citations
Single-cell sequencing reveals resistance-linked malignant subcluster in LUAD, confirming oncogenic role and CoxBoost + survivalSVM model achieves optimal C-index of 0.686 across seven cohorts.
Z. Qiu, Hui Zhao, Qiong Lyu et al.· Translational Oncology· 0 citations